London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
How the heck is it deramping ? If I could choose I would take sar rocketing to 10p any day of week. Yes it is falling and it is a brave man to buy and yes I will buy more if my pyc come in as I will have spare cash and would have made a bit on pyc. I’m not deramping I’m saying that I think it has some way to fall.
Utah - what’s this .. ****ging off SAR ( hoping to lower price) whilst on PYC aboard saying you predict a rise to 4p by end of week .. and you have already stated on one of these boards that once PYC gets to 7p you will sell and load up on SAR YOU NAUGHTY NAUGHTY DERAMPERS/RAMPER to try to influence people on each of your BBs to get what you want
This like the chase has been on since 2011 when this for to 5p. 9 years is it any further. People still talking about how this might come good. A big pharma, Christ even I'll be retired when this turns good. Personnly I think we are all being taken for the ride. All the share price has don is drift down. And dilute. So no real money in this at all. Same as val. They have done there investors over very badly. And they don't feel shame.
DISCLOSURE: Dr. Byers is a consultant/advisor for AbbVie, AstraZeneca, LUNGevity, PharmaMar, Genmab, Bristol-Myers Squibb, Sierra Oncology, and Alethia Biotherapeutics; and has received institutional research funding from AbbVie, Tolero Pharmaceuticals, Genmab, AstraZeneca, and Sierra Oncology.
Are not in a situation whereby they will take the first offer on the table. They aren’t that way of thinking. Having worked at Smithkline-beetcham and saw molecules become stuck in a backlog of numbers, they started millennium and worked on the forefront of tyk2 which was the IRAK molecule. They are extremely confident of their products, and just like with CHK1 , they will be looking for a proactive company to take the molecule and run with it and make it their sole concern. Pronai fitted that bill and have done very well in a short space of time in bioworld.
Hi All - Robin Davison is a one man PR machine for SAR.......got to love this guy.
*The TYK2 space has seen growing interest from investors, not least because of the potential in a number of autoimmune conditions and the fact they have become an area of interest for antitrust regulators in the pending Bristol-Myers Squibb-Celgene deal. The UK’s Sareum (SAR) has a preclinical TYK2/JAK1 inhibitor, SDC-1801, which is one of the few unpartnered assets in this particular class*.
Good old Robin Davison again, he's done more for Sareum than the chairman. You'll find Robin on twitter btw, worth a follow for his constant Sareum promotion. Picked up another chuck before close, must be less than a 2 year timescale now to check out.
I've got 2.5 million and a bonus coming the end of next month.I will buy more with that if still at this level. I don't think I've got a life changing amount but all JT needs is a tangible £500 million deal and he's a millionaire! And IMO it's a distinct posiblity that he will be.
Hi JT .. Amazing how quickly the No.Of Shares increases over time ... you will soon be one of the largest holders chasing after Thoth.... With a bit of luck it will make us all millionaires within a year or so I was going to top up further but i decided to put a chunk into PYC at 3.25 and its nicely up today ... so if it continues then I will sell out and have some additional funds for SAR at a later date My only concern is whether we have a deal maker .... as we continue to watch other deals and its never us ... One day PLEASE
Seems to be everyone except SAR in deal season .... can our BOD pull off a deal ? ... not yet able to and so going it alone with KY2T (for benefit of Parker) ... problem with that is it will lead to the need for more funding ... I think they hoped to get this from a milestone payment but SRRA dragging their heels ... for me it’s everything crossed that one of the BOD can deliver us a transformational deal ... here is hoping !!!
Pharmaceutical company Gilead Sciences Inc has entered into a "transformative" research and development partnership with Galapagos NV, Gilead announced on Sunday.
The deal, lasting for a decade, will see Gilead get access to Galapagos's "innovative" portfolio of compounds, including six molecules currently in clinical trials, 20 preclinical programs, and a "proven" drug discovery platform.
Gilead will make a USD3.95 billion upfront payment to Belgo-Dutch firm Galapagos, and also make a USD1.1 billion equity investment.
This will increase Gilead's stake in Galapagos to 22% from just over 12%. Gilead also will get two warrants which if exercised would give it a 30% stake, but it would not be able to increase the holding past that point for 10 years.
Gilead Chief Executive & Chair Daniel O'Day commented: "We are excited to enter into this unique agreement, which will generate both long-term strategic value and mutual, immediate benefits.
"We chose to partner with Galapagos because of its pioneering target and drug discovery platform, proven scientific capabilities and outstanding team."
"Gilead also gains exclusive access to all current and future compounds in Galapagos' rich pipeline while Galapagos is able to expand its research activities and build commercial infrastructure," he continued.
"The collaboration reflects Gilead's intent to grow our innovation network through diverse and creative partnerships."
Gilead shares closed 0.1% higher on Friday in New York at USD66.26 each.